DUBLIN, Ireland & INGELHEIM, Germany--(BUSINESS WIRE)--Elan plc (NYSE: ELN) and Boehringer Ingelheim today announced that they have entered into a global technical development and manufacturing agreement for antibody-based therapeutics.
DUBLIN, Ireland & INGELHEIM, Germany--(BUSINESS WIRE)--Elan plc (NYSE: ELN) and Boehringer Ingelheim today announced that they have entered into a global technical development and manufacturing agreement for antibody-based therapeutics.
